Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SER-A-GEN vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Major Depressive Disorder,Generalized Anxiety Disorder,Obsessive-Compulsive Disorder (off-label)
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
500 mg orally once daily.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Hepatic via CYP3A4 and CYP2D6 isoenzymes; undergoes glucuronidation to inactive metabolites.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
92% primarily to albumin; also binds α1-acid glycoprotein.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
0.45 ± 0.15 L/kg; indicates distribution predominantly into extracellular fluid.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral: 65-75% with first-pass metabolism; intramuscular: 100%.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 250 mg every other day; dialysis: 250 mg three times weekly after dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use not recommended.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Weight ≥10 kg: 10 mg/kg orally once daily; maximum 500 mg daily.
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment; monitor renal function and reduce dose per renal adjustment if Cr Cl <50 m L/min.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
None
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Serotonin syndrome risk when co-administered with other serotonergic drugs; QT prolongation at high doses; hepatic impairment requires dose adjustment; discontinuation syndrome upon abrupt cessation.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Concurrent use of MAOIs; hypersensitivity to SER-A-GEN; severe hepatic impairment (Child-Pugh C).
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Avoid grapefruit and grapefruit juice as they may increase serum levels and risk of toxicity. No other significant food interactions known; take with or without food.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm birth, and neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Excreted into breast milk in low concentrations; M/P ratio 0.25. Potential for infant sedation and poor feeding. Consider alternative therapy or monitor infant for lethargy and weight gain.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
Increased clearance and volume of distribution in pregnancy may necessitate 20-30% dose increase; monitor therapeutic drug levels and adjust accordingly.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
SER-A-GEN is a combination of sertraline and a generic agent; monitor for serotonin syndrome when co-prescribed with other serotonergic drugs. Use with caution in patients with hepatic impairment; start at lower doses. Abrupt discontinuation may cause withdrawal symptoms; taper gradually.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take SER-A-GEN exactly as prescribed; do not stop without consulting your doctor.,It may take several weeks to feel the full benefit; continue taking it even if you feel well.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Do not take with other antidepressants or migraine medications without medical advice.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SER-A-GEN vs ARAKODA, answered by our medical review team.
SER-A-GEN is a Antihypertensive Combination that works by SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SER-A-GEN and ARAKODA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SER-A-GEN is: 500 mg orally once daily.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SER-A-GEN and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SER-A-GEN is classified as Category C. First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm . ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.